Munagala Radha, Donà M Gabriella, Rai Shesh N, Jenson Alferd B, Bala Nagarajan, Ghim Shin J, Gupta Ramesh C
James Graham Brown Cancer Center, University of Louisville, Louisville, KY 40202, USA.
Int J Oncol. 2009 Jan;34(1):263-71.
Human papilloma virus (HPV) is the major cause of invasive cervical cancer (ICC). The study aim was to determine the prevalence of HPV genotypes and to correlate HPV types with response to radiotherapy. A total of 43 cervical biopsies collected from sequentially enrolled patients were analyzed by DNA amplification with MY09/MY11 primers and sequenced to determine the HPV genotype. Samples with multiple infections were resolved by multiplex PCR, combined with array primer extension (APEX). HPV DNA was detected in 40 of 43 (93%) samples. Nine different HPVs, including the most common types -16 (53%) and -18 (13%) were detected. Other types were HPV 31, 33, 45, 52, 58, 66 and 68. Single HPV types were found in 33 of 40 samples (82%) and multiple types in 7 of 40 samples (18%). The following significant predictors were identified: a) HPV 58 was most significant (p=0.02), followed by HPV 18 (p=0.04) associated with lack of treatment response; b) tumor size (p=0.042) and treatment response (p=0.025) elicited association with HPV infection type; c) treatment failure were found to be nearly 5-fold higher in case of multiple infections than of single infection (57% versus 12%) (odds ratio = 9.66; 95% CI 1.6-6.00). d) Multiple HPV infections correlated most prominently with lack of treatment compared with single type infection (p=0.005). Hence, patients with multiple infections, large tumor size, and HPV 58 and/or 18, are at risk of treatment failure and need to be followed for response and suitable inter-ventions done for a favorable outcome.
人乳头瘤病毒(HPV)是浸润性宫颈癌(ICC)的主要病因。本研究旨在确定HPV基因型的流行情况,并将HPV类型与放疗反应相关联。对连续入组患者采集的43份宫颈活检样本进行分析,采用MY09/MY11引物进行DNA扩增并测序以确定HPV基因型。多重感染样本通过多重PCR结合引物延伸芯片技术(APEX)进行分析。43份样本中有40份(93%)检测到HPV DNA。检测到9种不同的HPV,包括最常见的16型(53%)和18型(13%)。其他类型为HPV 31、33、45、52、58、66和68。40份样本中有33份(82%)为单一HPV类型,7份(18%)为多种类型。确定了以下显著预测因素:a)HPV 58最为显著(p=0.02),其次是与治疗反应缺乏相关的HPV 18(p=0.04);b)肿瘤大小(p=0.042)和治疗反应(p=0.025)与HPV感染类型相关;c)多重感染患者的治疗失败率比单一感染患者高近5倍(57%对12%)(优势比=9.66;95%可信区间1.6 - 6.00)。d)与单一类型感染相比,多重HPV感染与治疗缺乏最显著相关(p=0.005)。因此,多重感染、肿瘤体积大以及感染HPV 58和/或18的患者有治疗失败的风险,需要密切关注反应情况并采取适当干预措施以获得良好预后。